Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury

This study has been terminated.
(24 months of longterm follow up have been completed without substantial change to the profile. No further studies are currently planned)
Sponsor:
Information provided by:
Tengion
ClinicalTrials.gov Identifier:
NCT00512148
First received: August 3, 2007
Last updated: August 9, 2011
Last verified: August 2011

August 3, 2007
August 9, 2011
July 2007
January 2010   (final data collection date for primary outcome measure)
  • Change in Maximum Detrusor Pressure From Baseline to 12 Months [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Detrusor pressure is measured using urodynamic testing, which involves inserting a catheter through the urethra and into the bladder and measuring the pressure in the bladder as it is filled with fluid. The primary outcome measure for this study was the change in the maximum pressure observed during bladder filling from baseline to 12 months. The goal of the therapy was to decrease pressure.
  • Overall Safety Profile - Number of Participants Experiencing an Adverse Event [ Time Frame: through month 12 ] [ Designated as safety issue: Yes ]
    Clinical evaluation of adverse events, laboratory parameters and urinary imaging to assess any safety issues emerging from this technology and to allow a comparison of a safety profile with standard of care enterocystoplasty. Please refer to adverse event section for detailed information.
Maximum detrusor pressure and safety evaluation [ Time Frame: 12 months ]
Complete list of historical versions of study NCT00512148 on ClinicalTrials.gov Archive Site
Urodynamic Measurements and Long Term Safety [ Time Frame: month 12 through month 60 ] [ Designated as safety issue: No ]
maximum detrusor pressure, bladder capacity, frequency of incontinence episodes, long term safety [ Time Frame: periodically within first 12 months, as well as during long term follow up out to 5 years ]
Not Provided
Not Provided
 
Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury
An Open Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury

Subjects with neurogenic bladder secondary to spinal cord injury that is refractory to medical treatment and requires augmentation cystoplasty will be enrolled. The hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will reduce maximum detrusor pressure.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Neurogenic Bladder
Other: Autologous neobladder construct
augmentation cystoplasty with autologous neo-bladder construct
Experimental: 1
Receipt of autologous neo-bladder construct
Intervention: Other: Autologous neobladder construct
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
April 2011
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • subjects with neurogenic bladders secondary to spinal cord injury

Exclusion Criteria:

  • prior augmentation procedures or urinary diversion
  • recent urologic or intraperitoneal surgery or device implantation
  • recent history of spinal cord injury of less than a year
  • recent neurologic surgery
  • requirement for concomitant urological surgical procedures
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00512148
TNG-CL004
Yes
Sunita Sheth, MD Chief Medical Officer, Tengion, Inc
Tengion
Not Provided
Study Director: Sunita Sheth, MD Tengion, Inc
Tengion
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP